Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

Completed · Phase 3

Conditions studied: Menopause, Postmenopausal Vaginal Atrophy

In brief

This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.

Key facts

Study ID

NCT00108849

Run by

Novo Nordisk A/S

People needed

309

Starts

2005-03-01

Expected to finish

2007-05-01

Last updated by the study team

2017-02-08

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women whose last menstruation was at least two years previously

Where it is running

• Novo Nordisk Investigational Site — Montgomery, Alabama, United States
• Novo Nordisk Investigational Site — Phoenix, Arizona, United States
• Novo Nordisk Investigational Site — Tucson, Arizona, United States
• Novo Nordisk Investigational Site — Carmichael, California, United States
• Novo Nordisk Investigational Site — Palo Alto, California, United States
• Novo Nordisk Investigational Site — San Diego, California, United States
• Novo Nordisk Investigational Site — San Diego, California, United States
• Novo Nordisk Investigational Site — Denver, Colorado, United States
• Novo Nordisk Investigational Site — Denver, Colorado, United States
• Novo Nordisk Investigational Site — Lakewood, Colorado, United States
• Novo Nordisk Investigational Site — New London, Connecticut, United States
• Novo Nordisk Investigational Site — Clearwater, Florida, United States
• Novo Nordisk Investigational Site — Daytona Beach, Florida, United States
• Novo Nordisk Investigational Site — Palm Springs, Florida, United States
• Novo Nordisk Investigational Site — Plantation, Florida, United States
• Novo Nordisk Investigational Site — Tampa, Florida, United States
• Novo Nordisk Investigational Site — West Palm Beach, Florida, United States
• Novo Nordisk Investigational Site — Alpharetta, Georgia, United States
• Novo Nordisk Investigational Site — Roswell, Georgia, United States
• Novo Nordisk Investigational Site — Boise, Idaho, United States
• Novo Nordisk Investigational Site — Peoria, Illinois, United States
• Novo Nordisk Investigational Site — Evansville, Indiana, United States
• Novo Nordisk Investigational Site — Lexington, Kentucky, United States
• Novo Nordisk Investigational Site — Laurel, Maryland, United States
• Novo Nordisk Investigational Site — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.